|Bid||66.59 x 1200|
|Ask||66.63 x 800|
|Day's Range||65.99 - 66.79|
|52 Week Range||60.42 - 75.00|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||72.89|
|Earnings Date||Nov 19, 2018 - Nov 23, 2018|
|Forward Dividend & Yield||0.60 (0.91%)|
|1y Target Est||79.08|
Agilent Technologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
NEW YORK, Oct. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Backed by Illumina, the synthetic biology company is a rarity among life sciences IPOs: It has revenue. It also is in the middle of a potentially big lawsuit with Agilent and has a unique deal with Microsoft.
Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.
In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018. The enterprise value of Agilent is $22.11 billion, and its enterprise-value-to-revenue ratio is 4.6x. Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 3.6x.
Agilent Technologies (A) operates in three business segments: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab
Agilent Technologies (A) incurred selling, general, and administrative expenses of $339 million in the third quarter of 2018 compared to $308 million in the third quarter of 2017 due to higher commissions, acquisition costs, and an increase in personnel costs.
Agilent Technologies (A) has been on an acquisition spree through the third quarter of 2018. In May, it acquired all the remaining shares of Lasergen, an emerging biotechnology company engaged in developing technologies for DNA sequencing. Agilent also acquired 100% of the stock of Genohm, an international lab informatics company for ~$41 million.
Agilent Technologies (A) generated total revenues of $1.2 billion in the third quarter of 2018 compared to $1.11 billion in the third quarter of 2017. Agilent generates revenues from product sales and services. For fiscal 2018 and 2019, Agilent is expected to generate revenues of $4.88 billion and $5.18 billion, respectively, compared to $4.47 billion in fiscal 2017.
Moody's Investors Service ("Moody's") affirmed the Baa2 senior unsecured ratings for Agilent Technologies, Inc. ("Agilent"). The affirmation reflects Moody's view that Agilent will continue to maintain a strong credit profile with an excellent market position, strong cash flows, and moderate financial leverage.
Agilent (A) agrees to acquire ACEA Biosciences (ACEA) for $250 million, in a bid to expand its share in the cell analysis market.
Cell Analysis Just Got Better! ACEA Biosciences announced today that it has signed a definitive agreement to join Agilent Technologies, Inc. (NYSE:A). ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries.
Combined clinical reagent and instrument portfolio allows for optimized complete solutions. Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic growth initiative,” said Jacob Thaysen, president of Agilent’s Life Sciences and Applied Markets Group.
The U.S. administration will begin to levy new tariffs of 10 percent on about $200 billion of Chinese products on Sept. 24, with the tariffs to go up to 25 percent by the end of 2018. The following are comments made by U.S. companies after the Trump administration said on July 10 https://reut.rs/2m6Yu0r that it would slap tariffs on $200 billion of Chinese imports. ** Walmart Inc (WMT.N) warned that it may raise prices of products if the Trump administration imposes a tariff on Chinese imports.
Agilent Technologies Inc. (NYSE:A) today announced that a quarterly dividend of 14.9 cents per share of common stock will be paid on October 24, 2018, to all shareholders of record as of the close of business on October 2, 2018. Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions.
Agilent Technologies Inc. filed a new complaint against Twist Bioscience Corp. and Emily Leproust. The proposed Second Amended Complaint adds two additional defendants and adds new facts that were recently discovered regarding the defendants’ wide-ranging theft of Agilent’s proprietary oligonucleotide synthesis technology.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting A. A credit default swap spreads are within the middle of their range for the last three years.
Analyst Patrick Donnelly maintained a Buy rating on Agilent Technologies Inc (NYSE: A) and increased the price target from $77 to $82. The analyst added Agilent to Goldman's Americas Conviction List and also named it as a top pick. At the same time, Donnelly downgraded shares of Thermo Fisher Scientific Inc. (NYSE: TMO) from Buy to Neutral and maintained a $250 price target.
Thermo Fisher Scientific Inc. shares slid 1.9% Monday, after Goldman Sachs downgraded the stock to neutral from buy on valuation grounds. Goldman removed Thermo Fisher from its Americas Conviction List and added Agilent Technologies Inc. , which it now deems its top pick in life science tools and diagnostics. Agilent shares rose 0.5%. "We see this as an opportunistic time to make the switch to A given the set-up and valuation, with Agilent providing a rare Tools opportunity to own an accelerating growth story at a reasonable valuation with untapped capital allocation upside that could potentially be unlocked by the new CFO in our view," analysts wrote in a note. On Thermo, "we believe our thesis for deal-driven accelerating growth and margin expansion has been more appropriately reflected in valuation while the company faces a difficult set of comps starting in 4Q18," they wrote. Goldman is still positive on the fundamentals of both companies, and expects beats and raises in the next few quarter. Analysts raised their stock price target for Agilent to $82 from $77, but kept its stock price target for Thermo at $250. Thermo shares have gained 29% since they were added to Goldman's Conviction List. Shares have gained 25% in 2018, while Agilent has gained 3.3%. The S&P 500 has gained 8%.
A look at the shareholders of Agilent Technologies Inc (NYSE:A) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insidersRead More...